Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lion’s mane mushroom (Hericium erinaceus) is under scientific investigation for its neuroprotective properties, which has prompted interest in its potential use for supporting or treating neurodegenerative diseases such as Parkinson’s Disease (PD). Preclinical studies—primarily in vitro (cell culture) and in animal models—have shown that lion’s mane extracts may stimulate the synthesis of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), both of which are important for neuron survival and function. Some rodent studies suggest that lion’s mane may protect dopaminergic neurons (the type most affected in PD) and improve motor function after neurotoxic injury. The mushroom’s bioactive compounds, such as hericenones and erinacines, are thought to be responsible for these effects due to their ability to cross the blood-brain barrier and reduce oxidative stress and inflammation.

However, current evidence is limited to laboratory and animal research; there are no robust clinical trials in humans with Parkinson’s Disease published as of mid-2024. While early results are promising, they do not yet justify clinical use as a treatment for PD. Lion’s mane is not part of traditional Parkinson’s Disease therapies, but it is used in traditional East Asian medicine more broadly for cognitive health. The overall scientific evidence supporting its use for Parkinson’s is preliminary, warranting a rating of 2/5. Further research, especially controlled human trials, is necessary to establish both safety and efficacy in this context.

More about lion's mane
More about Parkinson's Disease

Other ingredients used for Parkinson's Disease

Other health conditions supported by lion's mane

Products containing lion's mane